Gentulizumab in Relapsed/Refractory Acute Myelogenous Leukemia or Myelodysplastic Syndrome

Clinical trial NCT05263271 · TERMINATED

Trial details

NCT number: NCT05263271
Sponsor: Changchun GeneScience Pharmaceutical Co., Ltd.
Status: TERMINATED
Phase: Phase 1
Study type: INTERVENTIONAL

Acute Myelogenous Leukemia Myelodysplastic Syndromes

Start date: 2021-04-01
Primary completion: 2024-12-02
Enrollment: 58

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.